Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity by Svirshchevskaya, Elena V et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Rapamycin delays growth of Wnt-1 tumors in spite of suppression 
of host immunity
Elena V Svirshchevskaya*1,2, Jacopo Mariotti2, Mollie H Wright2, 
Natalia Y Viskova1, William Telford2, Daniel H Fowler2 and 
Lyuba Varticovski2
Address: 1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Miklukho-Maklaya Street 16/10, Moscow 117997, Moscow, Russia and 
2National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD 20892, USA
Email: Elena V Svirshchevskaya* - esvir@mail.ibch.ru; Jacopo Mariotti - mariottj@mail.nih.gov; Mollie H Wright - writghtmo@mail.nih.gov; 
Natalia Y Viskova - visk@mail.ibch.ru; William Telford - telfordw@mail.nih.gov; Daniel H Fowler - dhfowler@helix.nih.gov; 
Lyuba Varticovski - varticol@mail.nih.gov
* Corresponding author    
Abstract
Background:  Rapamycin, an inhibitor of mammalian target of Rapamycin (mTOR), is an
immunosuppressive agent that has anti-proliferative effects on some tumors. However, the role of
Rapamycin-induced immune suppression on tumor progression has not been examined.
Methods: We developed a transplantation model for generation of mammary tumors in syngeneic
recipients that can be used to address the role of the immune system on tumor progression. We
examined the effect of Rapamycin on the immune system and growth of MMTV-driven Wnt-1
mammary tumors which were transplanted into irradiated and bone marrow-reconstituted, or
naïve mice.
Results: Rapamycin induced severe immunosuppression and significantly delayed the growth of
Wnt-1 tumors. T cell depletion in spleen and thymus and reduction in T cell cytokine secretion
were evident within 7 days of therapy. By day 20, splenic but not thymic T cell counts, and cytokine
secretion recovered. We determined whether adoptive T cell therapy enhances the anti-cancer
effect using ex vivo generated Rapamycin-resistant T cells. However, T cell transfer during
Rapamycin therapy did not improve the outcome relative to drug therapy alone. Thus, we could
not confirm that suppression of T cell immunity contributes to tumor growth in this model.
Consistent with suppression of the mTOR pathway, decreased 4E-BP1, p70 S6-kinase, and S6
protein phosphorylation correlated with a decrease in Wnt-1 tumor cell proliferation.
Conclusion: Rapamycin has a direct anti-tumor effect on Wnt-1 breast cancer in vivo that involves
inhibition of the mTOR pathway at doses that also suppress host immune responses.
Background
Breast cancer is the most frequent type of neoplasm
among women accounting for almost 30% of all tumor
cases. The estimated incidence in USA for 2007 is
180,000. In spite of advances in early detection and treat-
ment, death rates have not changed significantly. There-
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fore, the development of new drugs for treatment of breast
cancer is an area of active research. Rapamycin (sirolimus)
is an antifungal antibiotic possessing immunosuppressive
and anti-tumor activity by inhibiting the mTOR pathway.
Rapamycin delays tumor growth in some mouse models
including ErbB2 model of breast cancer [1-3]. However,
20–25% of established breast cancer cell lines are resistant
to Rapamycin [4] and multiple molecular mechanisms of
resistance to Rapamycin and Rapamycin-like drugs (RLD)
have been proposed [5]. In addition, clinical trials involv-
ing Rapamycin or other mTOR inhibitors have shown
only relatively modest responses in 7–30% of cancer
patients [6-8]. Phenotypic characterization and microar-
ray profiling of breast tumors reveal that distinct subtypes
of breast carcinoma are associated with different survival
rates and response to therapies. Five major groups of inva-
sive breast carcinomas have been identified: luminal A,
luminal B, HER2+/ER-, basal-like, and normal breast-like
[9]. A previous report showed that transgenic mammary
tumors driven by Erb-B2 are sensitive to Rapamycin [3].
Thus, a specific subset of breast cancer patients may bene-
fit from this type of therapy.
Wnt-1 was first identified as a protooncogene activated by
viral insertion in mouse mammary tumors. Transgenic
expression of MMTV-regulated Wnt-1 gene causes exten-
sive ductal hyperplasia and mammary adenocarcinomas
in transgenic mice [10]. Although Wnt-1 itself has not
been implicated in human breast neoplasms, other Wnt
family members are overexpressed in human breast can-
cer and there is growing evidence that Wnt pathway con-
tributes to maintenance of cancer stem cells [11]. There
are no reports on the role of Rapamycin in Wnt driven
mammary tumors.
Rapamycin and several RLD, such as CCI-779, RAD001,
and AP23573, have been introduced into clinical trials as
anti-cancer agents. These agents generally have tolerable
safety profiles, although rash, nausea, leukopenia, hyper-
glycemia, thrombocytopenia, and depression occur in
5–70% of patients [6-8]. When evaluated as single agents,
RLDs demonstrated clinical efficacy in mantle cell lym-
phoma (overall response rate of 38%) and glioblastoma
(36%), but low response rates in locally advanced and
metastatic breast (9.2%), renal cell (7%), and neuroendo-
crine carcinomas (5.6%) [6-8,12,13].
Mammalian TOR (mTOR) is a serine/threonine kinase
involved in intracellular signaling [14]. It plays a central
role in cell growth regulation by integrating signals from
growth factors, nutrients, and stress events. Constitutive
activation of mTOR-related messengers, including S6
kinase, eukaryotic translation initiation factor 4E-binding
protein kinase (4E-BP1), and ribosomal protein S6 occurs
in numerous malignancies [14-16]. mTOR plays a central
role in growth regulation of immune cells, leading to
severe immunosuppression, and Rapamycin is widely
used for maintenance of immunosuppression in trans-
plant patients. However, the specific effects of Rapamycin
on immune cells are still not well defined.
Long lasting thymus depletion after in vivo Rapamycin
treatment was found in mice and rats; and decreased
peripheral lymphoid cells occurred only in rats [17-19].
Since mTOR plays a central role in determining the out-
come of antigen recognition, Rapamycin induces anergy
rather than activation of T cells [20]. In addition, Rapamy-
cin treatment induces T regulatory cell enrichment due to
the low proliferative capacity of these cells in humans [21]
and mice [22], and preferentially inhibits Th1 and Tc1 cell
generation as compared to type 2 T cell immune responses
[23]. This immune cell dysfunction induced by Rapamy-
cin has been proposed to accelerate tumor growth. There-
fore, augmentation of specific subpopulations of immune
cells through adoptive cell therapy may improve outcome
in Rapamycin-treated recipients in vivo.
Among the many cell types which play a role in tumor
eradication, type 1 CD4+ Th1 and CD8+ Tc1 lymphocytes
(T1 cells) which secrete high levels of IFN-γ are proposed
to be most relevant [24,25]. Recently, we developed ex-
vivo T cell expansion protocol that permits generation of
immune competent Rapamycin-resistant Th1/Tc1 (T1) or
Th2/Tc2 (T2) cells [26].
In this study, we determined the anti-cancer effect of
Rapamycin in Wnt-1 mouse model of breast cancer and
also the effect of Rapamycin treatment on the cellular
composition and function of lymphoid organs in vivo. We
used Wnt-1 transgenic mammary tumor transplantation
model that allows generation of virtually unlimited num-
bers of synchronous transgenic tumors in syngeneic recip-
ients with remarkable stability of the genome [27-29]. We
also examined whether adoptive transfer of Rapamycin-
resistant T1 cells improves the anti-cancer effect.
Methods
Animals
C57BL/6 mice were purchased from Jackson Laboratory.
All mice were 6–8 wk old and maintained in pathogen-
free animal facility at the National Institutes of Health. All
studies were conducted in an AAALAC accredited facility
in compliance with the PHS Guidelines for the Care and Use
of Animals in Research.
Wnt-1 tumor growth and treatment in vivo
Wnt-1 tumor cells (1–2 × 105) were obtained as described
[27], and inoculated subcutaneously on the right flank or
into the left inguinal mouse fat pad (MFP #4). The injec-
tion of cells in 50 μl of PBS was performed through theBMC Cancer 2008, 8:176 http://www.biomedcentral.com/1471-2407/8/176
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skin of anesthetized mice. Experiments were conducted
either in intact non-irradiated naïve syngeneic recipients
or lethally irradiated (1050 cGy) mice using a137Cs
gamma radiation source (gamma Cell 40; Atomic Energy
of Canada). Irradiated mice were reconstituted with bone
marrow (5 × 106 cells/mouse) from syngeneic B6 mice
administered intravenously in 200 μl of PBS. Wnt-1 cells
were implanted on the same day following irradiation
and bone marrow reconstitution (5 to 10 mice per group).
A stock solution of Rapamycin (LP Laboratory, USA) was
made in ethanol at 1 mg/ml. Mice were given daily intra-
peritoneal injections of 30 μg of Rapamycin in 200 μl of
0.2% carboxymethyl-cellulose (Sigma) used as a diluent.
Rapamycin therapy was initiated on day 1 after tumor
implantation and continued for indicated times. Control
animals received injections with vehicle alone. Tumor size
was measured with vernier calipers twice a week and cal-
culated using the formula (W2 × L)/2, where W and L cor-
responded to width and length of tumors.
Preparation of mononuclear cells
Spleen and thymus cells were isolated by using stainless
steel 40 micron wire mesh. Bone marrow (BM) was
flushed from one femur and one tibia and made into sin-
gle cell suspensions by passing through 25 gauge needle.
Red cells were lysed by ACK buffer (Quality Biologicals,
Gaithersburg, MD). Cells were washed twice in phosphate
buffered saline (PBS) and transferred to complete
medium (CM) consisting of RPMI 1640 (Mediatech,
Herndon, VA) supplemented with 10% FCS (Gemini Bio-
Products, West Sacramento, CA), pen-strep-glut, non-
essential amino acids, and 2-ME 5 × 10-5 M (all from Inv-
itrogen Life Technologies, Carlsbad, CA).
Generation of T1Rapamycin cells using CD3 and CD28 
stimulation
To generate T cells that are resistant to Rapamycin, B-cells
were depleted from splenocytes using goat anti-mouse
magnetic particles (Polysciences, Warrington, PA). CD4
and CD8 cells were purified by CD4 enrichment kit
(StemCell Technologies, USA) and cultivated separately
to generate either Th1 or Tc1 cells as previously described
[26]. We have included Tc1 cells which are more likely to
mediate cytotoxic anti tumor responses and have persist-
ent in vivo survival (ibid). Briefly, to obtain Rapamycin
resistant T1 (1:1 Th1+Tc1) cells purified CD4+ or CD8+ T-
cells were stimulated with CD3/CD28 beads in the pres-
ence of N-acetyl-cysteine (3.3 mM; Bristol-Myers Squibb,
New York, NY), selective cytokines and 1 μM Rapamycin.
Anti-CD3 and anti-CD28-coated beads (CD3/CD28
beads) were produced according to previously developed
protocol [26] and used routinely in our laboratory at 3:1
(bead:cell) ratio. Conditioned medium was supple-
mented with recombinant murine IL-12 (2.5 ng/ml; R&D
Systems, Minneapolis, MN), recombinant human (rh)IL-
2 (20 IU/ml; National Cancer Institute (NCI)-Biologic
Resource Branch (BRB) Repository), rhIL-7 (20 ng/ml;
PeproTech, Rocky Hill, NJ), and anti-murine IL-4 (clone
11B.11 (10 μg/ml); NCI-BRB). Cytokine- and Rapamycin-
containing medium was added on days 0, 2, and 6 to
maintain 0.2–1.0 × 106 cells/ml. Addition of rmIL-12 was
performed only at day 0 of T1 culture. Before injection
into mice, T1 cells were analyzed by flow cytometry for
purity of preparation. Seven millions of Rapamycin resist-
ant T1 cells (T1Rapa) were injected in 200 μl of PBS intra-
venously into orbital sinus of mice at indicated times.
Isolation and in vitro cultures of primary cells from Wnt-1 
tumors
Tumor cell suspension was prepared as described for
other organs. Briefly, tumors were excised at 1 gm of wet
weight, cut into small pieces and tumor brei was prepared
by pressing through 40 micron wire mesh. Single cell sus-
pension was obtained by passing through 20–25 gauge
needles. Red cells were lysed as above. Cells were washed
twice in PBS and transferred into tissue culture plates
(Nunc, Rochester, NY) in CM for in vitro studies. Primary
cultures of tumor cells were depleted from contaminating
lymphocytes by seeding cells on 100 mm culture plates in
10 ml of CM for 24–72 hours. When adherent confluent
monolayer of tumor cells was formed, the plates were
washed vigorously with PBS, trypsinized, and Wnt-1 cells
were used for the analysis.
Generation of Wnt-1 cell lines
Wnt-1 cells obtained from tumors as above were seeded at
low density onto 90 mm tissue culture dishes. Single col-
onies were picked using cloning cylinders, and transferred
in CM to 96-well plate. Cells were incubated until conflu-
ence and transferred to 24-well plates. Two cell lines,
W1204 and W1308, with slightly different cellular mor-
phology were used for these studies.
Cell proliferation in vitro assay
Primary cultured Wnt-1 cells were seeded at 104 cells/well
in triplicates in 96-well plates. Serial dilutions of Rapamy-
cin at 10–0.01 mM in CM were added to the cells 24 hours
later. Cells were incubated for additional 96 hours and 1
μCi 3H-thymidin (Amersham) was added for the last 4
hours. Afterwards cells were harvested (Titertek, UK),
transferred onto glass filters, and dried. 3H-thymidin
incorporation was estimated by beta counter (BD, USA)
using scintillation liquid. As a control, intact splenocytes
(5 × 104 cells/well), studied in the same way, were incu-
bated in the presence of CD3/CD28 beads (1:1 ratio).
Flow cytometry analysis for surface markers
For the fluorescence-activated cell sorter (FACS) analysis
cells were transferred to FACS buffer (PBS, 1% bovine
serum albumin, 0.05% NaN3). Three-color flow cytome-BMC Cancer 2008, 8:176 http://www.biomedcentral.com/1471-2407/8/176
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try was performed using FACSCalibur instrument, Cel-
lQuest software (BD Biosciences) and the following
antibodies: Ep-CAM-FITC, mouse anti-vimentin, rat-anti-
mouse-FITC, anti-mouse CD3-FITC, CD4-PE, CD8-FITC,
CD25-PE, CD19-PE, NK1.1-PE, CD11b-FITC, and Fas-PE
(all from BD Pharmingen). Live events (5,000–10,000)
were acquired with propidium iodide exclusion of dead
cells.
Analysis of apoptosis by flow cytometry
Percentage of apoptotic cell was analyzed by AnnexinV
and 3,3'-dihexyloxacarbocyanine iodide (DiOC(6)) dou-
ble staining. The cationic lypophilic fluorochrome
DiOC(6) (Invitrogen) was used to evaluate transmem-
brane potential in mitochondria [30]. Splenocytes or
Wnt-1 cells were harvested, washed in pre-warmed PBS
supplemented with 2% of FCS, resuspended at 106 cells/
ml in PBS/2%FCS and 40 μM DiOC(6) and incubated for
30 minutes at 37°C. Cells were washed with PBS/2% FCS
and transferred to Annexin V binding buffer (Hepes
buffer, 10 mM, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2), stained with AnnexinV-APC and
propidium iodide (PI), incubated in the dark for 15 min,
and analyzed by flow cytometry.
Cytokine secretion analysis
Splenocytes were harvested from control or Rapamycin
treated animals at indicated times and prepared as single
cell suspension as above. Cells (106 cells/ml) were plated
in CM onto 24-well plates with or without CD3/CD28
beads. Supernatants were collected at 24 hours and
cytokines were measured by Bio-Plex multiplex sandwich
immunoassay (Bio-Rad) using Beadlyte Mouse Multi-
Cytokine Beadmaster kit (Upstate, Lake Placid, NY).
Cell cycle analysis
Cell cycle was analyzed using DAPI-stained DNA. Two
million cells were harvested at indicated time, washed in
ice-cold PBS, fixed by the addition of 70% ethanol and left
for 2 hours at 4°C. Thereafter, the cells were washed twice
in PBS, stained with 5 μg/ml of DAPI (Sigma Chemical
Co) in PBS and analyzed by FACS.
Scanning cytometry
Primary cultures of Wnt-1 cells were grown in 24-well
plates (Nunc, Rochester, NY) for 48–72 hours, then
washed in FACS buffer and stained with anti-mouse ep-
CAM-FITC antibodies. Wnt-1 cells were analyzed by laser
scanning cytometry (CompuCyte Corp., Boston, MA). The
fluorescence excitation was provided by a 488 nm argon
laser beam. The green fluorescence from FITC was meas-
ured using a 530/30-nm band-pass filter and amplified
using a photomultiplier.
Western blotting
After treatment with Rapamycin for indicated times, Wnt-
1 primary cultured cells were washed twice with PBS and
lysed in ice-cold lysis buffer (Cell Signaling Technology,
Danvers, MA). Lysates were centrifuged at 12,000 × g for
10 min at 4°C, and protein concentration of the cleared
cell lysates was measured using the Bio-Rad Protein Assay
kit (Bio-Rad Laboratories, Hercules, CA). Thirty micro-
grams of protein were denatured in SDS-sample buffer,
electrophoresed using 10% SDS-PAGE gels, transferred to
nitrocellulose membranes, and blocked for 1 h at room
temperature in TBS-T (50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 0.1% Tween-20) containing 5% non-fat milk.
Membranes were then incubated overnight at 4°C with
the indicated primary antibodies diluted 1:1000 in block-
ing solution. Antibodies against pp70S6K, S6K, pS6, p-
Akt, and Akt were from Translational Control Sampler Kit
(Cell Signaling, Beverly, MA). The appropriate secondary
antibodies conjugated to horseradish peroxidase (Santa
Cruz Biotechnology, CA) were used to visualize the bands
(1 h incubation) with an enhanced chemiluminescence
(ECL) visualization kit (Cell Signaling, Beverly, MA).
Statistical analysis
Statistical analysis was performed using Student's t-test.
Comparison values of p < 0.05 were considered statisti-
cally significant.
Results
Rapamycin delays Wnt-1 tumor growth in vivo
The effect of Rapamycin on growth of Wnt-1 tumors was
examined in syngeneic C57BL/6 mice implanted with
Wnt-1 tumor cells subcutaneously (s.c.) or into mouse fat
pad #4 (MFP). For these experiments, as few as 1–2 ×
105cells are sufficient to generate synchronous tumors
within 30 days. We used non-irradiated naïve mice or
lethally irradiated and bone marrow-reconstituted ani-
mals. Rapamycin treatment for 20 days resulted in a sig-
nificant delay in tumor growth evident by day 40 in naïve
(non XRT) and irradiated (XRT) hosts (Fig. 1A–C). The
differences in tumor growth rates between control and
Rapamycin treated mice were statistically significant as
determined by paired t-test. Similar results were obtained
using subcutaneous (s.c.) implantation of tumor cells
(105 cells/mouse) and 30 days of treatment with Rapamy-
cin (n = 8/group, Fig. 1A and 1D).
When the effect of Rapamycin on tumor growth in non-
irradiated and radiated animals was compared, it became
evident that tumors grew faster in irradiated hosts. Figure
1D summarizes the results obtained on day 60 for tumors
implanted s.c. and at day 50 for MFP tumors. Overall,
Wnt-1 tumors grew faster in MFP than when implanted
s.c. (Fig. 1D). Because growth of Wnt-1 tumors was also
accelerated in irradiated mice, we hypothesized that theBMC Cancer 2008, 8:176 http://www.biomedcentral.com/1471-2407/8/176
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effect of Rapamycin could be related to its immunosup-
pressive action. To dissociate antitumor and immunosup-
pressive activities, we determined the effect of Rapamycin
on Wnt-1 tumors and the immune system in vivo and in
vitro.
Rapamycin-induced suppression of immune system
To determine the level of immunosuppression induced by
Rapamycin, lymphocytes from in vivo treated mice were
analyzed at days 7 and 20 of treatment. At day 7, Rapamy-
cin treated recipients had a substantial decrease in thymo-
cytes and splenocytes (Fig. 2A). Although spleen cell
numbers almost normalized by day 20, thymocyte counts
remained severely depressed. There was no difference in
the total number of bone marrow cells before and after
Rapamycin treatment. Flow cytometry analysis on days 7
and 20 showed no significant difference in the proportion
of splenic CD3+, CD4+, CD8+, CD4+CD25+, CD19+,
NK1.1+, and CD11b+ cells (Additional file 1), demonstrat-
ing that different subpopulations of lymphocytes are sen-
sitive to Rapamycin to the same extent.
Rapamycin induces growth delay of Wnt-1 tumors Figure 1
Rapamycin induces growth delay of Wnt-1 tumors. Growth of Wnt-1 tumors implanted subcutaneously (S.C.) (A) or 
into MFP (B and C) of irradiated and bone marrow reconstituted (XRT, n = 10/group) (A and B) or naïve (no XRT, n = 5/
group) mice (C). D. Summary of the effect of irradiation and bone marrow reconstitution on the growth of Wnt-1 tumors 
implanted subcutaneously (S.C.) or into MFP. Data are presented as tumor volume at day 60 for s.c. and at day 50 for MFP 
after implantation. Mice were treated with 1.5 mg/kg of Rapamycin for 30 days in s.c. groups (A and D) or 20 days in MFP 
groups (B, C and D) starting the day after tumor implantation (arrows). Tumor size was calculated as described in Methods.
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Effect of Rapamycin on immune cells in vivo Figure 2
Effect of Rapamycin on immune cells in vivo. A. Cell number in lymphoid organs of mice implanted with Wnt-1 tumor 
and treated with Rapamycin in vivo for 7 and 20 days (n = 5/group). B and C. Spontaneous apoptosis in splenocytes from mice 
treated for 7 days with Rapamycin (B) or control mice (C). D. Cytokine production by CD3/CD28 stimulated splenocytes 
from control and in vivo Rapamycin treated mice at days 7 and 20 post treatment.
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To determine whether Wnt-1 tumor implantation also
had an effect on the immune system, an additional group
of mice was treated with Rapamycin in the presence or
absence of tumor. Implantation of tumors did not affect
the number of cells in these groups (Additional file 1). An
additional group of mice implanted with tumor cells but
not treated with Rapamycin was also included. Only mice
treated with Rapamycin showed a decrease in cell num-
bers. Thus, we concluded that immunosuppression was
induced solely by Rapamycin treatment and transplanta-
tion of Wnt-1 cell did not have a detectable effect on the
immune system in this model.
Rapamycin induced apoptosis of lymphoid cells
To determine whether the decrease in splenocyte numbers
found at day 7 of Rapamycin treatment was associated
with apoptosis, we stained freshly isolated splenocytes
from control and Rapamycin treated animals with DiOC6.
In Rapamycin treated group, 30 to 60% of splenocytes
were apoptotic as indicated by DiOC6 staining (Fig. 2B).
In contrast, control mice had only 10 to 18% apoptotic
splenocytes (Fig. 2C). Similar results with 25 to 52% of
splenocytes in apoptotic fraction were obtained at day 20
of treatment with Rapamycin (data not shown).
To evaluate the function of residual lymphocytes in
Rapamycin treated animals, splenocytes were harvested at
day 7 and 20 of therapy and co-stimulated with CD3 and
CD28 antibodies. Cytokine production was found only in
CD3/28 stimulated cultures. T cell cytokine secretion was
completely blocked by Rapamycin on day 7 (Fig. 2D).
However, by day 20 of therapy, splenic T cell cytokine
secretion recovered probably due to generation of
Rapamycin resistant T cells. Rapamycin did not induce a
shift away from Th1-type cytokines, since IFN-gamma
production was predominant in control (day 0) and 20
day treated groups (Fig. 2D).
Adoptive transfer of T1 cells resistant to Rapamycin did 
not affect Wnt-1 tumor growth
As it was shown above, Rapamycin induced apoptosis in
splenocytes. On the other hand XTR also accelerated Wnt-
1 tumor growth. We hypothesized that injection of
Rapamycin resistant T-cells could synergize with rapamy-
cin in tumor control. T1Rapa cells are resistant to rapamy-
cin, while host T cells undergo apoptosis after rapamycin
therapy initiation. Besides, T1Rapa cells are fully differen-
tiated effector cells of all specificities able to execute their
function immediately after the contact with specific tar-
gets. Hypothetically this could provide some advantages,
i.e.: i) in case immune response to tumor antigens is pos-
sible, some of these cells would proliferate quicker than
naïve T-cells; ii) tumor antigens are presented by MHC
class II molecules, which mostly stimulate Th1 or Th2
responses; while Tc1 cells are more likely to mediate cyto-
toxic anti tumor responses; iii) these cells are rather long
living as it was determined in our previous paper [26].
To estimate the effect of Rapamycin resistant T1 cells
(T1Rapa) on Wnt-1 tumor growth, irradiated and BM
reconstituted mice were inoculated with tumor cells and
injected either at day 5 or day 20 post transplant with 7 ×
106  cells/mouse of T1Rapa cells. Adoptive transfer of
T1Rapa cells did not reduce the growth of Wnt-1 tumors
(Fig. 3A).
Effects of T1Rapa cells on Wnt-1 tumor growth in vivo Figure 3
Effects of T1Rapa cells on Wnt-1 tumor growth in vivo. A. Tumor 
growth in lethally irradiated and BM reconstituted mice implanted s.c. with 
Wnt-1 tumor cells (2 × 105/mouse). T1Rapa cells (7 × 106/mouse, 1:1 of 
CD4:CD8) were injected intravenously at day 5 or 20 after tumor implan-
tation (shown with arrows). B. Tumor growth in lethally irradiated and BM 
reconstituted mice implanted with Wnt-1 tumor cells (105/mouse) into 
MFP and treated with Rapamycin from day 0 to day 20. T1Rapamycin cells 
(7 × 106/mouse, 1:1 of CD4:CD8) were injected intravenously at day 21 
after tumor implantation (shown with an arrow).
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Although Rapamycin therapy delayed tumor growth, this
effect was transient and tumor growth occurred after ces-
sation of therapy. We tested whether adoptive transfer of
T1Rapa cells at the end of Rapamycin treatment may delay
tumor re-growth. Sequential Rapamycin therapy for 20
days followed by T1Rapa cell transfer injected on day 21
did not change Wnt-1 tumor growth as compared with
Rapamycin alone (Fig. 3B). Thus, Wnt-1 tumor growth
was inhibited by Rapamycin, but not by adoptive T1Rapa
cell therapy.
Direct effect of Rapamycin on Wnt-1 cells proliferation in 
vitro
To evaluate the cellular mechanisms operational during
Rapamycin induced inhibition of Wnt-1 growth we
obtained purified primary tumor cells in vitro. Tumor cells
were plated in culture medium for 2–3 days, and non-
adherent cells were removed. More than 90% of the
remaining adherent cells had epithelioid morphology
(Fig. 4A) and were positive for epithelial cell Ep-CAM
marker as determined by scanning cytometry (Fig. 4B).
Additional characterization included identification of
vimentin-positive myoepithelial cells which constituted
less than 2% (data not shown).
The effect of Rapamycin on primary Wnt-1 tumor cell pro-
liferation was determined in vitro on cells obtained from
individual mouse tumors. Rapamycin inhibited prolifera-
tion of Wnt-1 cells, as well as normal lymphocytes, in a
wide range of concentrations (0.1 to 50 μM), and was
toxic at a concentration above 100 μM (Fig. 4C and 4D).
Inhibition of Wnt-1 cell proliferation by Rapamycin was
30–50%, and growth inhibition of splenocytes was
50–90%. There was no difference in in vitro Rapamycin
sensitivity between in vivo Rapa-treated or vehicle-treated
cells (data not shown).
Suppression of mTOR pathway by Rapamycin in primary 
Wnt-1 tumor cells
The effect of Rapamycin on the mTOR pathway was fur-
ther examined in short-term primary cultures of Wnt-1
tumor cells and in two clonal cell lines established from
these tumors. Phosphorylated Akt kinase, which activates
Akt and directly phosphorylates mTOR, and expression of
mTOR downstream messengers were present in all
tumors, but their intensity varied in primary cells from
different individual mice (Fig. 5A). Nine primary tumors
were analyzed. Among others, 3 were like culture #1, and
#2 last were like cultures #2 and #3, accordingly. We can
see in samples #2 and #3 increased level of phosphor-
ylated Akt kinase, while decreased amount of mTOR
products. The reason for such variability is non known.
This could be due to variable response of primary cells to
tissue culture conditions. Phosphorylation of mTOR asso-
ciated proteins was reduced by Rapamycin in 5 of 9 cul-
tured tumors. We also generated two stable cell lines from
two different primary tumors, and tested their response to
Rapamycin after ten passages in vitro. Both cell lines were
sensitive to Rapamycin with decreased phosphorylation
of p70S6K and S6 ribosomal protein (Fig. 5B).
Rapamycin did not induce apoptosis or cell cycle arrest in 
Wnt-1 cells
Rapamycin has been shown to inhibit the proliferation of
T cells and some tumors by inducing cell cycle arrest in G1
followed by apoptosis [31,32]. We examined whether a
similar process occurs in Wnt-1 tumor cells. Wnt-1 pri-
mary cultured cells (n = 6) were incubated with Rapamy-
cin for 24 h. Freshly isolated splenocytes were used as
controls (n = 5). At 24 h, nearly 30% of splenocytes and
Wnt-1 cells were apoptotic in cultures exposed to media
alone (Fig. 6). Rapamycin increased the percent of apop-
totic splenocytes to 76% (Fig. 6A), but did not augment
apoptosis of Wnt-1 cells (Fig. 6B). Fig. 6C summarizes
data for Rapa-induced apoptosis in splenocytes and Wnt-
1 cells.
To test whether the failure of Rapamycin to induce apop-
tosis in Wnt-1 cells could be due to lack of Fas expression,
we examined its expression on ep-CAM+ primary cultures
of Wnt-1 cells. Fas expression was found in 2% to 10% of
Wnt-1 cells (Fig. 6D) while in 90% of activated spleno-
cytes (Fig. 6E). Thus, it is possible that reduced apoptotic
response of Wnt-1 cells could be due to low Fas expres-
sion.
We also determined the effect of Rapamycin on cell cycle
progression of primary Wnt-1 cultures and CD3/28 co-
stimulated splenocytes. Cells were incubated with
Rapamycin for 72 hours and then collected. There was no
difference between control and Rapamycin treated Wnt-1
cells, among them 80–88% of cells were found in G1
phase, and 12–18% in G2/S phase. In contrast, Rapamy-
cin induced cell cycle arrest in activated splenic T cells
where the percentage of cells in G1 phase increased from
56 to 77%, while in S phase the portion of cells decreased
from 33 to 10% (Fig. 7). This result demonstrates that
Rapamycin does not induce cell cycle arrest in Wnt-1 cells.
Discussion
Several Rapamycin-like drugs have been introduced into
clinical trials based on their potential antitumor effects [6-
8,12,13]; however, the role of immune suppression inher-
ent to these agents as related to their anticancer activity
has not been addressed. In our study, Rapamycin induced
severe immune deficiency with complete and sustained
depletion of thymus, decreased numbers of immune cells
in peripheral blood, transient depletion of spleen with
high rate of apoptosis in mature lymphocytes, and sup-
pressed cytokine production by T-cells within 7 days ofBMC Cancer 2008, 8:176 http://www.biomedcentral.com/1471-2407/8/176
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treatment. The immune function was partially recovered
on day 20 when the number of splenocytes and their abil-
ity to produce cytokines upon CD3/28 activation almost
returned to normal. This was probably due to the genera-
tion of Rapamycin-resistant population of T cells. Close
results were obtained in humans by Blazar B.R. and co-
authors [23] who showed that rapamycin treated alloge-
neic BM recipients had a marked decrease in donor tho-
racic duct lymphocytes T cell number between days 5 and
24 post-transplant. The same study also showed that the
lymphocytes had a decrease in Th1 or Tc1, but not Th2 or
Tc2 cytokine production [23]. Th2 shift after in vivo
rapamycin treatment was reported by several teams in
humans but not in mice [26,33]. Our results in mice did
not demonstrate a selective down-regulation of T1 cell
function based on the profile of cytokine production.
CD3/28 activated splenocytes from mice treated with
Rapamycin for 20 days had comparable cytokine profiles
to results in control mice.
Earlier it was shown that in vivo treatment of mice for 10
to 28 days with high doses of Rapamycin had no effect on
myelopoiesis, as measured by BM cellularity, proliferative
capacity, and number of colony-forming progenitors [34].
We also found that Rapamycin did not affect the BM cell
number at day 7 or 20. This finding is rather unexpected
because BM cell proliferate vigorously.
The role of T cells and especially of CD8+ cytotoxic T cells
in tumor surveillance has been widely studied and dis-
cussed [35,36]. In our study, Wnt-1 tumors grew slower in
non-irradiated mice than in irradiated, BM reconstituted
animals, suggesting that host immunity may contribute to
tumor progression. Given this information, we examined
the effect of Rapamycin-resistant CD8+ and CD4+ T-cells
on Wnt-1 tumor growth in vivo. We used T1 cells gener-
ated in vitro in the presence of Rapamycin using polyclo-
nal activation accompanied by cytokines which biased T1
differentiation, a method routinely used in our laboratory
[26]. Contrary to our hypothesis, we found that the adop-
Rapamycin inhibits Wnt-1 tumor cell proliferation Figure 4
Rapamycin inhibits Wnt-1 tumor cell proliferation. A and B. Morphology (A) and epithelial marker Ep-CAM expression 
(B) in primary Wnt-1 tumor cells. C and D. Proliferation of normal CD3/28 activated splenocytes (pooled from 5 mice) (C) or 
primary Wnt-1 cells from 3 different tumors (D). Cells were incubated with 1 μM of Rapamycin for 72 hours and proliferation 
was measured by 3H-thymidine incorporation.
A
Morphology of Wnt-1 cultures Ep-CAM-FITC staining
B
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tive transfer of Rapamycin-resistant T1 cells did not sup-
press Wnt-1 tumor growth or increase the therapeutic
efficacy of Rapamycin. Other T cell subsets or other
immune cells, such as dendritic cells, which can be inhib-
ited by either irradiation or rapamycin [37], play a role in
tumor progression in this model. Future efforts should be
directed towards evaluating alternative methods to pro-
mote immunity in the setting of rapamycin therapy.
Rapamycin and other RLD modulate G1- to S-phase pro-
gression in eukaryotic cells [38]. Rapamycin induced G1/
G2 cell cycle arrest and apoptosis of activated lym-
phocytes, but not Wnt-1 cells in vitro. These results are in
contrast to apoptosis induced by Rapamycin in primary
adult human ALL and ErbB2 tumor cells [2,3], and indi-
cate that inhibition of the mTOR pathway in Wnt-1 cells
leads to suppression of proliferation without cell cycle
arrest. These observations in vitro correlated with the delay
of tumor growth in vivo which was followed by recovery
after stopping the drug. Similar observations were found
in ErbB2 transgenic model, with rapid re-growth of tumor
after cessation of therapy [3].
Mammalian TOR forms two distinct functional com-
plexes, termed mTOR complex 1 and 2. Previous studies
indicate that Rapamycin inhibits the mTOR complex 1
pathway by blocking phosphorylation of p70 S6 kinase
(S6K1) and 4E-binding protein 1 (4E-BP1), both of which
are involved in protein translation and cell cycle progres-
sion [14]. In addition, prolonged exposure impairs forma-
tion of mTOR complex 2, resulting in decreased
phosphorylation of Akt [39]. Previous report showed that
over-expression of S6K1 and high level of phosphorylated
Akt correlate with sensitivity of breast cancer cells to
Rapamycin [4,16]. Rapamycin also inhibits angiogenic
responses in ErbB2 transgenic mouse mammary, human
hepatocellular carcinoma, and in corneal neovasculariza-
tion models [3,40-42] presumably by suppression of Akt-
dependent HIF-1 signaling [3]. Our data confirm that
Rapamycin has a direct effect on inhibition of the mTOR
pathway in Wnt-1 transgenic tumor cells in primary cul-
tures and in cell lines derived from these tumors with sup-
pression of proliferation and a decrease in
phosphorylated forms of S6K1, ribosomal protein S6, 4E-
BP1 and Akt. Additional mechanisms of Rapamycin
induced MMTV-Wnt-1 transgenic tumor suppression may
also play a role, including cell autophagy. Inhibition of
the mTOR pathway induces macroautophagy due to dep-
rivation of nutrients [43,44]. The transient suppression of
Wnt-1 tumor growth by Rapamycin suggests that it is
unlikely that these mechanisms play a significant role in
this model.
Downstream components of the Wnt signaling pathway
are specifically activated in a significant proportion of
breast tumors [reviewed in [45]]. Activation of Wnt path-
way induces expression of antiapoptotic genes in different
cells which allows these cells to resist apoptosis in
response to serum deprivation or induced by chemother-
apeutic drugs [46,47]. Several anti-apoptotic genes, such
as insulin-like growth factor (IGF) receptors, are induced
by Wnt signaling and addition of IGF-I rescued MCF-7
cells from antiproliferative effects induced by Rapamycin
[48]. The phosphorylation of S6K was sensitive to
Rapamycin and wortmannin, a PI3K inhibitor, but resist-
ant to U0126, a MEK inhibitor, which specifically inhibits
ERK phosphorylation. Thus, Wnt signaling may partially
override the effects of Rapamycin and prevent cell cycle
arrest and apoptosis as shown here for Wnt-1 mammary
tumor cells. In addition, Wnt directly stimulates mTOR
signaling via inhibiting glycogen synthase kinase 3
Effect of Rapamycin on mTOR signalling in Wnt-1 cells Figure 5
Effect of Rapamycin on mTOR signalling in Wnt-1 
cells. A. Cells from Wnt-1 cultured for 3–4 days were 
trypsinyzed, seeded into flasks in complete medium and incu-
bated overnight. Rapamycin (1 μM) was added for additional 
24 hours. Western blots of cellular extracts were stained 
with specific antibodies to phosphorelated forms of TOR 
pathway messengers. B. Western blots of cell extracts from 
Wnt-1 cell lines, W1308 and W1204.
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Rapamycin induces apoptosis of splenocytes but not Wnt-1 cells Figure 6
Rapamycin induces apoptosis of splenocytes but not Wnt-1 cells. A and B. Intact splenocytes (A) and cells from pri-
mary Wnt-1 cultures (B) were incubated with or without 1 μM Rapamycin for 24 hours, labeled with DiOC6 and stained with 
annexinV-APC. Representative contour plots for splenocytes and Wnt-1 culture are shown. Apoptotic cells are gated in a 
square in each panel. C. Percent of apoptotic cells (mean ± SD) is shown for 5 spleens and 6 Wnt-1 cultures. D and E. Expres-
sion of Fas on Wnt-1 cells (D) or activated splenocytes (E).
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(GSK3) dependent phosphorylation of tumor suppressor
TSC2 [49].
Conclusion
In conclusion, Wnt-1 mammary tumor transplanted into
syngeneic hosts is a valuable model for studying the effect
of immune system on cancer. Rapamycin has relatively
potent direct anti-tumor effect and induces severe
immune suppression that could potentially antagonize its
therapeutic efficacy. However, we did not observe that
adoptive T cell therapy synergizes with Rapamycin. Fur-
ther studies using Rapamycin and other RLD are necessary
to investigate the role of adaptive T cell transfer in other
models. In addition, the evaluation of RLD in breast can-
cers which overexpress Wnt family members is warranted.
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